REGISTER
Telitacicept: From Tertiary Hospitals to Grassroots Access
This article reviews telitacicept’s expansion from tertiary hospital prescription to grassroots access in China. Added to the 2026 National Essential Medicines List after Phase III success in lupus (NEJM 2025) and IgA nephropathy (NEJM 2026), the drug achieved 1.52 million doses in 2024 and 2.26 million in 2025, reaching 1,200+ hospitals. Key barriers remain: pricing, specialist physician training, and last-mile distribution.

At the rheumatology and immunology department of a tertiary Grade A hospital in a northern region with a high proportion of elderly patients, a chief physician — Dr. Li Wan (a pseudonym) — has long followed a patient with severe lupus. The patient's condition is now stable, with steroids continuously tapering. She no longer needs monthly visits to the tertiary hospital; instead, she self-injects telitacicept at home, much like insulin.

In July 2026, this domestic dual-target biologic was included in the National Essential Medicines List, the first comprehensive update in eight years. With the policy channel open, in theory, stable patients can visit a tertiary hospital once every three months and obtain their medication at a grassroots facility, then self-inject at home.

But for a self-injectable autoimmune biologic that has been on the market for more than five years and is rapidly expanding in market scale, how far is it from reaching community health centers and township hospitals?

A New Tool for Rheumatology

Rheumatology has long faced a shortage of physicians and treatments. According to Dr. Li Wan, telitacicept, as a domestic dual-target biologic, gives the department one more tool.

In October 2025, The New England Journal of Medicine published the Phase III results of telitacicept for systemic lupus erythematosus (SLE). At week 52, the modified SRI-4 response rate reached 67.1%, and 44.9% of patients achieved a reduction in prednisone dose. On immunological markers, telitacicept significantly reduced serum immunoglobulin levels and effectively increased complement C3 and C4 levels.

Real-world data are also noteworthy. A retrospective study of 41 SLE patients at Shengjing Hospital of China Medical University showed that, after 24 weeks of treatment, the SLEDAI-2K score fell from a baseline of 10.0 to 4.18, and the prednisone-equivalent dose decreased from 20.87 mg/day to 9.86 mg/day. Among 16 lupus nephritis patients, 24-hour proteinuria dropped from 2.81 g/day to 1.00 g/day. Adverse events were all mild to moderate, with no serious infections.

In myasthenia gravis (MG), a real-world study from Shenzhen involving 17 patients showed that 80% simultaneously met a composite endpoint of MG-ADL reduction ≥2 points and QMG reduction ≥3 points. The average daily prednisone dose dropped from 10.41 mg to 2.50 mg — a 76% relative reduction — and 3 patients discontinued steroids entirely. No serious adverse events occurred during the observation period.

In May 2026, NEJM published a second Phase III study of telitacicept, this time in IgA nephropathy. At week 39, the 24-hour urine protein-to-creatinine ratio fell by 58.9% from baseline, a 55% reduction after placebo adjustment. The geometric mean percent change in eGFR was -1.0% with telitacicept versus -7.7% with placebo. The proportion of patients with an eGFR decline of ≥30% was 6.3% in the telitacicept group versus 27.0% in the placebo group.

What struck Dr. Li Wan most was the route of administration. Telitacicept (including a formulation for IgA nephropathy) comes as a subcutaneous prefilled syringe, allowing patients to inject at home rather than repeatedly visiting the hospital. This feature breaks the traditional model in which biologics must be infused in a hospital and provides a physical prerequisite for grassroots access.

Efficacy and convenience have been demonstrated. The more practical question is whether patients can afford — and access — the drug.

From Medical Insurance Negotiation to the Essential Medicines List

Having worked on the wards for many years, Dr. Li Wan has encountered patients who were forced to interrupt biologic treatment for economic reasons.

Telitacicept was approved for SLE in 2021 and entered the medical insurance catalog that same year. After multiple rounds of negotiation, the current insurance price is approximately 778 yuan per dose. At the standard SLE dose of 160 mg per week, annual treatment costs roughly 81,000 yuan. With employee insurance typically reimbursing 85–95% (around 90% on average), patient out-of-pocket costs are about 8,100 yuan per year — roughly 675 yuan per month.

The price-for-volume effect is clear. Remegen’s 2024 annual report showed approximately 1.5245 million doses sold, up 94.87% year-over-year. In 2025, sales reached 2.255 million doses, up 47.92% year-over-year. By the end of 2024, telitacicept had been introduced in more than 1,000 hospitals; by the end of 2025, this had risen to more than 1,200.

The drug has also begun its overseas journey: in June 2025, Remegen licensed telitacicept’s ex-Greater China rights to Vor Bio in a deal worth USD 4.23 billion — comprising USD 125 million in cash and warrants, plus up to USD 4.105 billion in milestone payments.

On July 9, 2026, the National Health Commission and other departments released the 2026 National Essential Medicines List, the first comprehensive update in eight years. The new list adds 116 drugs (109 net new), including 16 innovative drugs — four of which are domestic Category I new drugs. The list takes effect on September 1, 2026.

Li Wan believes that the value of the Essential Medicines List lies in its downward extension. Patients with stable conditions can visit a Grade-III hospital once every three months. If medications are available at primary healthcare facilities, patients can obtain their prescriptions there and then return to higher-level hospitals for follow-up consultations. This benefits both two-way referral and long-term patient management.

But she is also realistic: the Essential Medicines List confers “list status” — it does not mean the drug is necessarily on the shelf at every hospital. Each hospital still has its own formulary process.

The list answers “is the drug available?” — not “who will use it?”

Drugs May Reach Grassroots; Specialists Still Need Training

Where is the biggest bottleneck in equipping grassroots facilities with biologics?

Li Wan believes that the issue lies with physicians. Even at primary healthcare institutions—even general practitioners—must have a certain degree of specialization. If there is a shortage of physicians knowledgeable in rheumatology and immunology, hospitals lack the professional expertise required to manage these medications. Primary-care physicians are unable to adequately handle patients referred from higher-level hospitals, and physicians at tertiary hospitals lack confidence in their colleagues’ability to manage such cases.

Specialty capacity in rheumatology does differ across tier 1, 2, 3, and 4 cities. The discipline is highly specialized and requires multidisciplinary collaboration. The further down you go, the harder it is to develop the specialty.

But Dr. Li Wan also sees the possibility of a virtuous cycle. With a drug available, there will be patients. With patients, doctors will pay attention to the disease. Once patients know the drug exists and have a stable physician, adherence improves — benefiting both patients and the specialty.

In practice, Dr. Li Wan notes that county-level and above hospitals she has contact with often already have access to B-cell-targeted therapies. Going further down to villages and clinics, however, she has not seen this situation. Asked about the ideal scenario of grassroots doctors dynamically prescribing based on patient indicators, she said: “We hope so too, but it requires a high level of specialist expertise. Right now, it may be a little difficult.”

Medicines come first, then patients; and only with patients can doctors grow—this is a summary of the development path for grassroots medical disciplines. However, growth takes time, while the pace at which medicines are being decentralized may already be ahead.

After the Essential Medicines List Opens the Channel

At a July 9, 2026 press conference, Gong Xiangguang, Director of the Drug Policy Division of the National Health Commission, stated that this adjustment attempted to include innovative drugs in the selection scope, exploring a feasible path for more innovative drugs to enter the Essential Medicines List in the future.

Remegen continues to expand telitacicept’s indications. SLE and MG are already covered by medical insurance; rheumatoid arthritis, Sjögren’s syndrome, and IgA nephropathy have all been approved. Under medical insurance catalog adjustment rules, newly approved indications can be applied for through a simplified renewal procedure, suggesting the latter three may enter medical insurance through this streamlined process.

The policy channel is open, clinical value has been demonstrated, and grassroots demand is real. What remains may not be a question that any single company or department can answer alone.

Returning to Dr. Li Wan’s many lupus patients — injecting telitacicept at home, tapering steroids, with stable disease — this is today’s reality in tertiary hospitals. The Essential Medicines List aims to make this scene possible in grassroots facilities. As Dr. Li Wan puts it: “We very much look forward to it.”

0
0
Loading